AMGN:NSD-Amgen Inc (USD)

COMMON STOCK | Drug Manufacturers-General | NSD

Last Closing Price

USD 241.66

Change

+3.92 (+1.65)%

Market Cap

USD 138.40B

Volume

2.50M

Average Target Price

USD 262.94 (+8.80%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Sensipar/Mimpara to treat secondary hyperparathyroidism; and EPOGEN to treat anemia caused by chronic kidney disease. It also markets other products in various markets, including Nplate, Vectibix, Repatha, Parsabiv, BLINCYTO, Aimovig, NEUPOGEN, Otezla, AMGEVITA, KANJINTI, EVENITY, IMLYGIC, MVASI, and Corlanor. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; QIAGEN N.V.; Adaptive Biotechnologies; and Eli Lilly and Company, as well as has a strategic agreement with McKesson Corporation to help improve cancer care in community oncology settings. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-01-14 )

Largest Industry Peers for Drug Manufacturers-General

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
AZN AstraZeneca PLC

+0.41 (+0.81%)

USD132.98B 53.56 17.48
SNY Sanofi

+0.99 (+2.06%)

USD120.21B 24.76 7.41
GILD Gilead Sciences, Inc

+0.86 (+1.40%)

USD77.14B 61.11 20.48
CELG Celgene Corporation

N/A

USD77.04B 13.33 10.62
BIIB Biogen Inc

+13.62 (+5.11%)

USD41.04B 8.78 5.89
GRFS Grifols, S.A

-0.10 (-0.52%)

USD17.48B 32.11 16.97
HZNP Horizon Therapeutics Public Li..

+1.81 (+2.35%)

USD17.02B 21.35 30.92
GWPH GW Pharmaceuticals plc

+4.98 (+3.75%)

USD4.14B 91.14 84.16

ETFs Containing AMGN

Symbol Name Weight Mer Price(Change) Market Cap
BBH VanEck Vectors Biotech ET.. 0.00 % 0.35 %

+1.95 (+1.10%)

USD0.48B
EKLD:PA BNP Paribas Easy MSCI USA.. 0.00 % 0.00 %

-0.02 (-0.14%)

N/A
EMWE:F BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

N/A

N/A
BBCK:F Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.30 (+0.83%)

USD0.03B
3SUR:F iShares MSCI USA SRI UCIT.. 0.00 % 0.33 %

-6.00 (-0.42%)

N/A
USRI:PA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.14 (-0.20%)

USD0.07B
EWRD:PA BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

+0.03 (+0.19%)

N/A
EMWE:PA BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

+0.05 (+0.35%)

N/A
EKUS:PA BNP Paribas Easy - MSCI U.. 0.00 % 0.00 %

-0.01 (-0.08%)

N/A
BUYB:PA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.43 (+1.17%)

USD0.03B
QDVG:F iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.02 (+0.22%)

USD1.69B
USFM:LSE UBS (Irl) ETF plc - MSCI .. 0.00 % 0.30 %

+0.25 (+0.01%)

N/A
SUAS:LSE iShares MSCI USA SRI UCIT.. 0.00 % 0.30 %

-0.03 (-0.22%)

N/A
XUHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

+0.14 (+0.28%)

USD1.21B
XSHC:LSE Xtrackers MSCI USA Health.. 0.00 % 0.12 %

-3.50 (-0.10%)

USD0.77B
UVAL:LSE SPDR MSCI USA Value UCITS.. 0.00 % 0.25 %

+0.36 (+1.02%)

USD0.10B
UC46:LSE UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

-87.50 (-0.72%)

N/A
SXLV:LSE SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.15 (+0.43%)

USD0.19B
SUWS:LSE iShares MSCI World SRI UC.. 0.00 % 0.00 %

+0.02 (+0.20%)

N/A
MJMT:F Amundi Index Solutions - .. 0.00 % 0.00 %

+0.24 (+0.30%)

USD0.36B
QDVR:F iShares MSCI USA SRI UCIT.. 0.00 % 0.30 %

-0.03 (-0.31%)

N/A
SUSW:LSE iShares MSCI World SRI UC.. 0.00 % 0.30 %

+0.02 (+0.24%)

N/A
MJMT:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

+0.28 (+0.35%)

USD0.36B
ZPDH:XETRA SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.13 (+0.45%)

USD0.19B
XUHC:XETRA Xtrackers MSCI USA Health.. 0.00 % 0.12 %

+0.18 (+0.46%)

USD1.21B
UIMP:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

-0.24 (-0.18%)

N/A
UET1:XETRA UBS ETF - MSCI USA Social.. 0.00 % 0.33 %

-0.05 (-0.21%)

N/A
UEFY:XETRA UBS ETF - SBI Foreign AAA.. 0.00 % 0.20 %

+0.02 (+0.14%)

USD0.18B
QDVR:XETRA iShares MSCI USA SRI UCIT.. 0.00 % 0.30 %

-0.02 (-0.18%)

N/A
QDVG:XETRA iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.04 (+0.53%)

USD1.69B
GNAR:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.18 (-0.25%)

N/A
UIMP:F UBS ETF - MSCI USA Social.. 0.00 % 0.28 %

-0.40 (-0.29%)

N/A
EWRD:XETRA BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

+0.02 (+0.17%)

N/A
EMWE:XETRA BNP Paribas Easy MSCI Wor.. 0.00 % 0.00 %

+0.07 (+0.49%)

N/A
EKLD:XETRA BNP Paribas Easy MSCI USA.. 0.00 % 0.00 %

-0.05 (-0.31%)

N/A
BBCK:XETRA Invesco Global Buyback Ac.. 0.00 % 0.39 %

+0.43 (+1.17%)

USD0.03B
3SUR:XETRA iShares MSCI USA SRI UCIT.. 0.00 % 0.33 %

-2.20 (-0.15%)

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.07 (+1.18%)

N/A
ZPRU:F SPDR MSCI USA Value UCITS.. 0.00 % 0.25 %

+0.59 (+1.51%)

USD0.12B
ZPDH:F SPDR S&P U.S. Health Care.. 0.00 % 0.15 %

+0.04 (+0.14%)

USD0.19B
SUUS:LSE iShares MSCI USA SRI UCIT.. 0.00 % 0.30 %

-5.75 (-0.70%)

N/A
SBUY:LSE Invesco Global Buyback Ac.. 0.00 % 0.39 %

+19.50 (+0.60%)

USD0.03B
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.75 (+1.33%)

USD0.03B
IYH iShares U.S. Healthcare E.. 0.00 % 0.43 %

-0.12 (-0.05%)

USD2.51B
QDYN FlexShares Quality Divide.. 0.00 % 0.37 %

+0.18 (+0.34%)

USD0.02B
QDF FlexShares Quality Divide.. 0.00 % 0.37 %

-0.05 (-0.10%)

USD1.43B
PKW Invesco BuyBack Achievers.. 0.00 % 0.62 %

+0.82 (+1.06%)

USD1.00B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

+1.13 (+1.50%)

USD0.35B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

+1.54 (+2.06%)

USD0.26B
LNGR Global X Longevity Themat.. 0.00 % 0.50 %

+0.02 (+0.07%)

USD0.05B
JHMH John Hancock Multifactor .. 0.00 % 0.40 %

-0.16 (-0.35%)

USD0.05B
IXJ iShares Global Healthcare.. 0.00 % 0.46 %

+0.09 (+0.12%)

USD2.48B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.04 (+0.50%)

USD1.54M
IBB iShares Nasdaq Biotechnol.. 0.00 % 0.47 %

+3.84 (+2.43%)

USD10.37B
FHLC Fidelity MSCI Health Care.. 0.00 % 0.08 %

+0.05 (+0.08%)

USD2.46B
FDRR Fidelity Dividend ETF for.. 0.00 % 0.29 %

+0.15 (+0.40%)

USD0.31B
EQWL Invesco S&P 100 Equal Wei.. 0.00 % 0.25 %

+0.15 (+0.21%)

USD0.07B
CURE Direxion Daily Healthcare.. 0.00 % 1.08 %

-0.75 (-0.89%)

USD0.14B
BLV Vanguard Long-Term Bond I.. 0.00 % 0.05 %

-0.92 (-0.86%)

USD12.07B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

-1.05 (-4.87%)

USD9.34M
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

+4.80 (+5.13%)

USD0.24B
RXD ProShares UltraShort Heal.. 0.00 % 0.95 %

+0.04 (+0.50%)

USD1.54M
RXL ProShares Ultra Health Ca.. 0.00 % 0.95 %

-0.81 (-0.50%)

USD0.12B
IUHC:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

+0.04 (+0.44%)

USD1.17B
FHI:CA CI First Asset Health Car.. 0.00 % 0.65 %

+0.03 (+0.27%)

USD0.19B
IHCU:LSE iShares S&P 500 Health Ca.. 0.00 % 0.15 %

-0.25 (-0.04%)

USD1.69B
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.09 (+1.24%)

USD0.22B
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.04 (+0.74%)

USD0.19B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.35 %

+0.09 (+1.25%)

USD0.22B
FHI-B:CA CI First Asset Health Car.. 0.00 % 0.65 %

N/A

N/A
HHL-U:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

+0.02 (+0.24%)

N/A
TPHD Timothy Plan High Dividen.. 0.00 % 0.52 %

+0.01 (+0.04%)

USD0.12B
LS:CA Middlefield Healthcare & .. 0.00 % 0.85 %

N/A

USD0.08B
FHI Federated Hermes, Inc 0.00 % 0.00 %

+0.63 (+2.07%)

N/A
RYH Invesco S&P 500 Equal Wei.. 0.00 % 0.40 %

-2.17 (-0.80%)

USD0.77B
HONR InsightShares Patriotic E.. 0.00 % 0.65 %

N/A

USD1.34M
LIFE aTyr Pharma, Inc 0.00 % 0.00 %

+0.16 (+4.06%)

USD0.04B
HHL:CA Harvest Healthcare Leader.. 0.00 % 0.85 %

+0.02 (+0.25%)

USD0.33B
ZBIO ProShares UltraPro Short .. 0.00 % 0.95 %

N/A

USD2.51M
XLV Health Care Select Sector.. 0.00 % 0.13 %

-0.37 (-0.32%)

USD25.69B
XHC:CA iShares Global Healthcare.. 0.00 % 0.63 %

-0.09 (-0.15%)

USD0.42B
VHT Vanguard Health Care Inde.. 0.00 % 0.10 %

+0.19 (+0.08%)

USD15.36B
UBIO ProShares UltraPro Nasdaq.. 0.00 % 0.95 %

N/A

USD0.02B
ZPRU:XETRA SPDR MSCI USA Value UCITS.. 0.00 % 0.25 %

+0.68 (+1.75%)

USD0.12B

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-General)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 5.11% 50% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.11% 50% F 46% F
Trailing 12 Months  
Capital Gain 0.48% 63% D 42% F
Dividend Return 2.66% 40% F 64% D
Total Return 3.14% 63% D 43% F
Trailing 5 Years  
Capital Gain 59.72% 63% D 57% F
Dividend Return 17.24% 60% D- 60% D-
Total Return 76.96% 63% D 58% F
Average Annual (5 Year Horizon)  
Capital Gain 10.96% 63% D 65% D
Dividend Return 2.94% 40% F 71% C-
Total Return 13.91% 75% C 68% D+
Risk Return Profile  
Volatility (Standard Deviation) 12.06% 100% A+ 84% B
Risk Adjusted Return 115.31% 88% B+ 95% A
Market Capitalization 138.40B 100% A+ 99% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-General)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.17 88% B+ 51% F
Price/Book Ratio 12.43 13% F 13% F
Price / Cash Flow Ratio 15.13 63% D 26% F
EV/EBITDA 12.45 75% C 63% D
Management Effectiveness  
Return on Equity 67.18% 100% A+ 99% A+
Return on Invested Capital 19.48% 75% C 91% A-
Return on Assets 9.45% 88% B+ 95% A
Debt to Equity Ratio 278.61% 13% F 6% F
Technical Ratios  
Short Ratio 2.82 50% F 49% F
Short Percent 1.20% 100% A+ 76% C
Beta 0.76 38% F 76% C
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High dividend returns

The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.